Literature DB >> 31566078

The clinical characteristics of systemic lupus erythematosus patients in Indonesia: a cohort registry from an Indonesia-based tertiary referral hospital.

L Hamijoyo1,2, S Candrianita2, A R Rahmadi1, S Dewi1,2, G Darmawan2, B S Suryajaya2, N R Rainy2, I I Hidayat2, V N Moenardi2, R G Wachjudi1,2.   

Abstract

INTRODUCTION: To date, no national epidemiological data of systemic lupus erythematosus are available in Indonesia.
OBJECTIVE: We aimed to demonstrate clinical characteristics of systemic lupus erythematosus patients of the Dr Hasan Sadikin General Hospital, one of Indonesia's top tertiary-referral hospitals.
METHOD: We reviewed retrospective cohort data from the Hasan Sadikin Lupus Registry, which was created in January 2016. Initial retrospective data were collected from the medical records of systemic lupus erythematosus patients from 2008 to 2015 and enhanced the cohort data from January 2016 to December 2017. The records were analysed for age, sex, clinical manifestations, comorbidity, treatment and outcome.
RESULTS: Of 813 patients, 95.6% were females. Mean age at diagnosis was 27.7 ± 9.4 years, with a mean disease duration of 76.5 ± 53.1 months. Major clinical manifestations were arthritis (75.5%) and malar rash (68.3%). The majority of patients received steroid treatment, beside chloroquine and azathioprine. In total, 93 patients (11.4%) developed tuberculosis, 522 patients (64.2%) had routine follow-up and 66 patients (8.1%) died. Infection was the most common cause of death (36.4%).
CONCLUSION: Arthritis and malar rash were the most commonly encountered clinical manifestations in the Hasan Sadikin Lupus Registry. Tuberculosis incidence in systemic lupus erythematosus patients was high, as was the mortality rate of lupus.

Entities:  

Keywords:  Indonesia; Systemic lupus erythematosus; clinical characteristic; registry

Mesh:

Year:  2019        PMID: 31566078     DOI: 10.1177/0961203319878499

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  7 in total

1.  Factors associated with active tuberculosis in Colombian patients with systemic lupus erythematosus: a case-control study.

Authors:  Luis Alonso González-Naranjo; Jaime Alberto Coral-Enríquez; Mauricio Restrepo-Escobar; Carlos Horacio Muñoz-Vahos; Daniel Jaramillo-Arroyave; Adriana Lucía Vanegas-García; Ruth Eraso; Gloria Vásquez; Fabián Jaimes
Journal:  Clin Rheumatol       Date:  2020-06-11       Impact factor: 2.980

2.  Tuberculosis Among Patients With Systemic Lupus Erythematosus in Indonesia: A Cohort Study.

Authors:  Laniyati Hamijoyo; Edhyana Sahiratmadja; Nadia G Ghassani; Guntur Darmawan; Evan Susandi; Reinout van Crevel; Philip C Hill; Bachti Alisjahbana
Journal:  Open Forum Infect Dis       Date:  2022-04-12       Impact factor: 4.423

3.  Activity Disease in SLE Patients Affected IFN-γ in the IGRA Results.

Authors:  Winni Maharani; Dwi Febni Ratnaningsih; Fitria Utami; Fajar Awalia Yulianto; Anneke Dewina; Laniyati Hamijoyo; Nur Atik
Journal:  J Inflamm Res       Date:  2020-08-14

4.  Nigella sativa L. as immunomodulator and preventive effect on renal tissue damage of lupus mice induced by pristane.

Authors:  Zahrah Hikmah; Anang Endaryanto; I Dewa Gede Ugrasena; Anny Setijo Rahaju; Syaiful Arifin
Journal:  Heliyon       Date:  2022-04-06

5.  Incidence and prevalence of tuberculosis in systemic lupus erythematosus patients: A systematic review and meta-analysis.

Authors:  Qian Wu; Yang Liu; Wei Wang; Yu Zhang; Kui Liu; Song-Hua Chen; Bin Chen
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

Review 6.  Clinical Research Progress of Small Molecule Compounds Targeting Nrf2 for Treating Inflammation-Related Diseases.

Authors:  Zhenzhen Zhai; Yanxin Huang; Yawei Zhang; Lili Zhao; Wen Li
Journal:  Antioxidants (Basel)       Date:  2022-08-12

7.  Correlation Between Steroid Therapy and Lipid Profile in Systemic Lupus Erythematosus Patients.

Authors:  Nur Atik; Rira Uji Hayati; Laniyati Hamijoyo
Journal:  Open Access Rheumatol       Date:  2020-03-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.